Skip to content
2000
Volume 7, Issue 2
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

COVID-19 is caused by a new SARS-CoV-2 virus from the Coronaviridae family, responsible for developing severe acute respiratory syndrome (SARS-CoV). Its emergence in 2019 presented several challenges to global health. The virus can infect host cells using the ACE2 receptor, and after infection, several clinical manifestations appear, ranging from mild symptoms to death. One approach that has shown promising results is convalescent plasma since convalescent plasma (CP) consists of a concentrate of immunoglobulins in the blood of patients recently infected with the coronavirus for those currently infected. Therefore, this therapy uses antibodies in the plasma to neutralize the virus. This literature review aims to evaluate the efficacy of CP therapy in symptomatic COVID-19 patients by analyzing clinical trials and studies published between 2020 and 2023. Therefore, the search identified studies in which the majority reported the efficacy of using convalescent plasma to treat and alleviate the clinical condition of patients diagnosed with COVID-19. Important factors influence the efficacy of CP therapy, such as the timing of administration and the severity of the disease. Early administration in mild and moderate cases has shown promise. Furthermore, molecular docking analysis suggests that antibodies can cause conformational changes in the SARS-CoV-2 spike protein, raising the hypothesis that using CP may interfere with viral entry into host cells.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975333030241010011753
2024-10-22
2026-02-22

  • From This Site

    /content/journals/covid/10.2174/0126667975333030241010011753
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WHO, Coronavirus Disease (COVID-19) Dashboard.Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1
  2. ChanJ.F.W. YuanS. KokK.H. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster.Lancet20203951022351452310.1016/S0140‑6736(20)30154‑9 31986261
     [Google Scholar]
  3. YadavR. ChaudharyJ.K. JainN. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19.Cells202110482110.3390/cells10040821 33917481
     [Google Scholar]
  4. WallsA.C. ParkY.J. TortoriciM.A. WallA. McGuireA.T. VeeslerD. Structure, function, and antigenicity of the sars-cov-2 spike glycoprotein.Cell20201812281292.e610.1016/j.cell.2020.02.058 32155444
     [Google Scholar]
  5. AstutiI. Ysrafil Severe acute respiratory syndrome coronavirus 2 (sars-cov-2): An overview of viral structure and host response.Diabetes Metab. Syndr.202014440741210.1016/j.dsx.2020.04.020 32335367
     [Google Scholar]
  6. LiL. TongX. ChenH. Characteristics and serological patterns of COVID ‐19 convalescent plasma donors: Optimal donors and timing of donation.Transfusion20206081765177210.1111/trf.15918 32627216
     [Google Scholar]
  7. Pulcheri RamosR. Sonoe Ota-ArakakiJ. Thrombosis and anticoagulation in COVID-19.J. Bras. Pneumol.2020464e2020031710.36416/1806‑3756/e20200317 32696836
     [Google Scholar]
  8. SahebnasaghA. AvanR. SaghafiF. Pharmacological treatments of COVID-19.Pharmacol. Rep.20207261446147810.1007/s43440‑020‑00152‑9 32816200
     [Google Scholar]
  9. DawoodA.A. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir).Adv. Med. Sci.20236811910.1016/j.advms.2022.10.001 36368287
     [Google Scholar]
  10. KhaliliJ.S. ZhuH. MakN.S.A. YanY. ZhuY. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19.J. Med. Virol.202092774074610.1002/jmv.25798 32227493
     [Google Scholar]
  11. OmraniA.S. SaadM.M. BaigK. Ribavirin and interferon alfa-2a for severe middle east respiratory syndrome coronavirus infection: A retrospective cohort study.Lancet Infect. Dis.201414111090109510.1016/S1473‑3099(14)70920‑X 25278221
     [Google Scholar]
  12. BenjaminR.J. McLaughlinL.S. Plasma components: Properties, differences, and uses.Transfusion201252s1Suppl. 19S19S10.1111/j.1537‑2995.2012.03622.x 22578375
     [Google Scholar]
  13. PandeyS. VyasG.N. Adverse effects of plasma transfusion.Transfusion201252s1Suppl. 165S79S10.1111/j.1537‑2995.2012.03663.x 22578374
     [Google Scholar]
  14. GouletD.R. AtkinsW.M. Considerations for the design of antibody-based therapeutics.J. Pharm. Sci.202010917410310.1016/j.xphs.2019.05.031 31173761
     [Google Scholar]
  15. TillerK.E. TessierP.M. Advances in antibody design.Annu. Rev. Biomed. Eng.201517119121610.1146/annurev‑bioeng‑071114‑040733 26274600
     [Google Scholar]
  16. BradleyB.J. CarlsonJ.R. A gas-liquid chromatographic procedure for the determination of indole and 3-methylindole in bovine plasma.Anal. Biochem.197459121421910.1016/0003‑2697(74)90027‑X 4407485
     [Google Scholar]
  17. JiangS. HillyerC. DuL. Neutralizing antibodies against sars-cov-2 and other human coronaviruses.Trends Immunol.202041535535910.1016/j.it.2020.03.007 32249063
     [Google Scholar]
  18. FDA2021Available from: https://www.fda.gov/
  19. P. FHNAnnals of internal medicine review meta-analysis : Convalescent blood products for spanish influenza.Ann. Intern. Med.2006145
     [Google Scholar]
  20. HungI.F.N. ToK.K.W. LeeC.K. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.Clin. Infect. Dis.201152444745610.1093/cid/ciq106 21248066
     [Google Scholar]
  21. Mandal Amit KumarI.O. Dam PaulamiL. Since january 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-.Ann. Oncol.20201921
     [Google Scholar]
  22. Mair-JenkinsJ. Saavedra-CamposM. BaillieJ.K. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis.J. Infect. Dis.20152111809010.1093/infdis/jiu396 25030060
     [Google Scholar]
  23. GarraudO. Use of convalescent plasma in Ebola virus infection.Transfus. Apheresis Sci.2017561313410.1016/j.transci.2016.12.014 28094110
     [Google Scholar]
  24. AllahyariA. Seddigh-ShamsiM. MahmoudiM. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.Int. Immunopharmacol.20219310723910.1016/j.intimp.2020.107239 33582019
     [Google Scholar]
  25. AbolghasemiH. EshghiP. CheraghaliA.M. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.Transfus. Apheresis Sci.202059510287510.1016/j.transci.2020.102875 32694043
     [Google Scholar]
  26. ErkurtM.A. SariciA. Berberİ. Kukuİ. KayaE. ÖzgülM. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.Transfus. Apheresis Sci.202059510286710.1016/j.transci.2020.102867 32620409
     [Google Scholar]
  27. ShenoyA.G. HettingerA.Z. FernandezS.J. BlumenthalJ. BaezV. Early mortality benefit with COVID‐19 convalescent plasma: A matched control study.Br. J. Haematol.2021192470671310.1111/bjh.17272 33482025
     [Google Scholar]
  28. LindemannM. LenzV. KnopD. Convalescent plasma treatment of critically ill intensive care COVID‐19 patients.Transfusion20216151394140310.1111/trf.16392 33784412
     [Google Scholar]
  29. GreenbaumU. KleinK. MartinezF. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients.Front. Immunol.20211267567910.3389/fimmu.2021.675679 33995420
     [Google Scholar]
  30. DonatoML ParkS BakerM Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with hightiter convalescent plasma.JCI Insight2021601210.1172/jci.insight.143196
     [Google Scholar]
  31. GharbharanA JordansCCE GeurtsvanKesselC Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.Nat. Commun.2021121318910.1038/s41467‑021‑23469‑2 34045486
     [Google Scholar]
  32. BalcellsM.E. RojasL. Le CorreN. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.PLoS Med.2021183e100341510.1371/journal.pmed.1003415 33657114
     [Google Scholar]
  33. SimonovichV.A. Burgos PratxL.D. ScibonaP. A randomized trial of convalescent plasma in covid-19 severe pneumonia.N. Engl. J. Med.2021384761962910.1056/NEJMoa2031304 33232588
     [Google Scholar]
  34. De SantisG.C. OliveiraL.C. GaribaldiP.M.M. High-dose convalescent plasma for treatment of severe COVID-19.Emerg. Infect. Dis.202228354855510.3201/eid2803.212299 35081022
     [Google Scholar]
  35. SturekJ.M. ThomasT.A. GorhamJ.D. Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile.Microbiol. Spectr.2022101e02560e2110.1128/spectrum.02560‑21 35196802
     [Google Scholar]
  36. OrtigozaM.B. YoonH. GoldfeldK.S. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients.JAMA Intern. Med.2022182211510.1001/jamainternmed.2021.6850 34901997
     [Google Scholar]
  37. SelfW.H. WheelerA.P. StewartT.G. Neutralizing COVID-19 convalescent plasma in adults hospitalized with COVID-19.Chest2022162598299410.1016/j.chest.2022.06.029 35780813
     [Google Scholar]
  38. AlsharidahS. AyedM. AmeenR.M. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.Int. J. Infect. Dis.202110343944610.1016/j.ijid.2020.11.198 33285283
     [Google Scholar]
  39. HabtehyimerF. ZhuX. ReddA.D. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: A randomized controlled trial.Microbiol. Spectr.2024121e03286e2310.1128/spectrum.03286‑23 38009954
     [Google Scholar]
  40. RazumikhinM. SmolyanovaT. NikolaevaA. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.Immunotherapy202214141133114710.2217/imt‑2022‑0015 35892311
     [Google Scholar]
  41. McConnellS.A. SachithanandhamJ. MudrakN.J. Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization.Cell Chem. Biol.2023307726738.e410.1016/j.chembiol.2023.05.011 37354908
     [Google Scholar]
  42. TimofeevaA.M. ShayakhmetovaL.S. NikitinA.O. Natural antibodies produced in vaccinated patients and COVID-19 convalescents hydrolyze recombinant RBD and nucleocapsid (N) proteins.Biomedicines2024125100710.3390/biomedicines12051007 38790969
     [Google Scholar]
  43. WangL. ZhaoJ. NguyenL.N.T. Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma.Sci. Rep.2021111555810.1038/s41598‑021‑84840‑3 33692386
     [Google Scholar]
  44. DenkingerC.M. JanssenM. SchäkelU. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: A randomized clinical trial.Nat. Cancer2022419610710.1038/s43018‑022‑00503‑w 36581734
     [Google Scholar]
  45. SouzaP.F.N. MesquitaF.P. AmaralJ.L. The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape.Int. J. Biol. Macromol.202220810512510.1016/j.ijbiomac.2022.03.058 35300999
     [Google Scholar]
/content/journals/covid/10.2174/0126667975333030241010011753
Loading
Antibodies as Promising Molecules to Block Spike Glycoprotein from SARS-CoV-2
Coronaviruses 7, E26667975333030 (2026); https://doi.org/10.2174/0126667975333030241010011753
/content/journals/covid/10.2174/0126667975333030241010011753
/content/journals/covid/10.2174/0126667975333030241010011753
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): ACE2 receptor; antibodies; convalescent plasma; COVID-19; immunoglobulins; SARS-CoV-2 treatment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test